Is there a refillable injection pen for semaglutide?

What does a semaglutide injection pen actually look like?

The Wegovy pen is a slim, pre-filled auto-injector made by Novo Nordisk. It comes loaded with semaglutide solution at a single fixed dose, you cannot adjust the strength or top it up. Each pen holds four weekly doses, so one pen lasts a month. A needle is pre-attached for the first injection; you swap in a new needle before each subsequent dose, then replace the pen cap between uses.

The mechanism is simple: dial to the correct dose marker, hold the pen against your skin at the recommended injection site, and press the button. There is no drawing up of solution, no glass vial to handle, and nothing to refill. That is by design, pre-filled pens reduce handling errors and help keep the medicine stable.

Once the four doses are used, the pen is empty. At that point it goes into a sharps container for safe disposal; a 1-litre sharps bin is suitable for home use. The next pen arrives with your following monthly order, already loaded at whatever dose your prescriber has set for that cycle.

Why does a 'refillable' semaglutide pen keep coming up in searches?

The short answer: cost. Pre-filled pens generate pharmaceutical-grade packaging at every refill, and some people reasonably wonder whether a cartridge or vial format would be cheaper or more sustainable. A handful of compounding pharmacies in the United States have produced unlicensed semaglutide formulations in vials, which has fed the idea that a refillable pen format must exist somewhere. It does not, not in any UK-licensed product. The semaglutide injections available through licensed UK pharmacies come exclusively in the pre-filled disposable format.

There is also occasional confusion with insulin delivery. Insulin pens do commonly use refillable cartridge systems. Semaglutide has a different formulation, concentration and dosing frequency (it is given once weekly rather than multiple times daily) and Novo Nordisk has not developed a cartridge system for the UK market. The pre-filled pen format is the only option your prescriber can legally supply.

Searching for a refillable pen sometimes also reflects a worry about sustainability. Both Wegovy and Ozempic pens contain plastic components; Novo Nordisk runs take-back programmes in some markets, though the UK picture is still developing. If this matters to you, it is worth raising with your prescriber or pharmacist.

Does the needle change between doses count as 'refilling'?

In a narrow sense, yes, you are replacing a component. But the pen body and the medicine inside it are fixed; you are not adding semaglutide. Changing the needle is a basic hygiene step, not a refill: a used needle becomes blunt and carries contamination risk, so a fresh one is fitted before every injection. Novo Nordisk supplies spare needles in the box, and replacement packs are available separately if you run short.

The reason this matters clinically is that some people mistake the needle-change instruction for an optional extra. It is not. Reusing a needle increases the chance of an incorrect dose, injection-site reactions and infection. The NHS semaglutide patient information is clear on this point, and it is worth reading the Patient Information Leaflet that comes with your pen for the full step-by-step guidance.

If you want to explore how the pen fits into the broader semaglutide pen landscape (different strengths, the titration schedule, what each dose looks like in practice) our prescribers work through exactly these questions during the consultation.

What about the oral semaglutide tablet, does that avoid the pen question entirely?

For some people, yes. The MHRA approved an oral semaglutide tablet (Wegovy tablets) in June 2026, making it the first GLP-1 medicine licensed in the UK for weight management that requires no injection at all. It is taken once daily, first thing in the morning, on an empty stomach with a small amount of plain water, at least 30 minutes before food or drink. No pen, no needle, no sharps disposal.

Trial evidence from the OASIS 4 study found roughly 13.6% average weight loss over 64 weeks, and around 17% among those who adhered fully to treatment throughout. That second figure is notable, though it applies to the fully-adherent group specifically, not the trial average. For context on what Wegovy as a whole offers, the Wegovy treatment overview covers both formats.

Whether the injection or the tablet is more appropriate is a clinical question. Absorption, tolerability and your medical history all feed into that decision. There is no universally right answer; that is precisely why a prescriber reviews your case individually rather than a form deciding for you. If you are curious about the cost side of things, Wegovy pricing in the UK covers what to expect from private treatment. And if needles are the sticking point, raising that directly during your consultation is the right move, our prescribers hear it often.